Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Significant Increase in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 584,609 shares, a growth of 823.5% from the July 30th total of 63,307 shares. Currently, 9.0% of the company’s shares are sold short. Based on an average daily volume of 38,485,659 shares, the days-to-cover ratio is currently 0.0 days.

Creative Medical Technology Stock Down 1.7%

Shares of NASDAQ:CELZ opened at $1.22 on Wednesday. Creative Medical Technology has a 52-week low of $0.62 and a 52-week high of $6.25. The stock has a market cap of $8.03 million, a price-to-earnings ratio of -0.59 and a beta of 1.94. The business has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.76.

Creative Medical Technology (NASDAQ:CELZ) last posted its earnings results on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). As a group, equities analysts anticipate that Creative Medical Technology will post -1.18 EPS for the current fiscal year.

Institutional Trading of Creative Medical Technology

Large investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new stake in Creative Medical Technology during the 4th quarter valued at about $59,000. Clear Harbor Asset Management LLC acquired a new position in shares of Creative Medical Technology during the 2nd quarter worth approximately $192,000. Finally, Seros Financial LLC purchased a new stake in shares of Creative Medical Technology in the second quarter valued at approximately $53,000. 1.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CELZ has been the subject of several research reports. Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a report on Thursday, August 20th. Wall Street Zen raised shares of Creative Medical Technology to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings upgraded shares of Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Creative Medical Technology presently has an average rating of “Hold”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.